Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Quantum Biopharma Ltd. - Class B Subordinate Voting Shares (NQ:QNTM)

18.10 +1.57 (+9.50%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Quantum Biopharma Ltd. - Class B Subordinate Voting Shares

< Previous 1 2 3 4 5 6 Next >
BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances IND Application for Lucid-MS with Final Toxicity Reports
Via Investor Brand Network
Quantum BioPharma Receives Final Reports for Two Key Studies of its Potential Breakthrough Drug for Multiple Sclerosis, Moving Closer to Phase 2 Clinical Trial
From Quantum BioPharma
Via GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Appoints Dr. Jack Antel as Clinical Advisor for MS Program
Via Investor Brand Network
Why Is Quantum BioPharma In The News Today? Here’s An Important Update On Its Multiple Sclerosis Investigational Drug
Via Stocktwits
Quantum BioPharma Welcomes World-Renowned Multiple Sclerosis Expert Dr. Jack Antel as Clinical Development Advisor For Lucid-MS Trials
From Quantum BioPharma
Via GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Reports Results of Annual General and Special Meeting
Via Investor Brand Network
Quantum BioPharma Ltd. Announces Results of Annual General and Special Meeting of Shareholders
From Quantum BioPharma
Via GlobeNewswire
Quantum BioPharma Licensee Unbuzzd Wellness to Host Live Webinar and Q&A Session on Wednesday, October 1, 2025
From Quantum BioPharma
Via GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Receives Health Canada Product License for Qlarity
Via Investor Brand Network
Health Canada Grants Quantum BioPharma a Product License for Its Innovative Product, Qlarity™, that Enhances Energy, and Promotes Metabolism, Mental Alertness and Cognitive Performance
From Quantum BioPharma
Via GlobeNewswire
BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Licensee Unbuzzd Wellness to Host Investor Webinar on Sept. 16
Via Investor Brand Network
Quantum BioPharma Licensee Unbuzzd Wellness to Host Investor Webinar on September 16, 2025 at 1:30 PM PT
From Quantum BioPharma
Via GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Receives BUY Rating, $45 Price Target from Kingswood Capital Partners
Via Investor Brand Network
Kingswood Capital Partners Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$45 Price Target
This was unpaid research with no consideration given 
From Quantum BioPharma
Via GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) Provides Corporate Update
Via Investor Brand Network
Quantum BioPharma Announces Corporate Updates
From Quantum BioPharma
Via GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) to Seek Shareholder Approval for $600K Private Placement
Via Investor Brand Network
Why Quantum BioPharma (QNTM) Stock Is Soaring Today
Shares of Quantum BioPharma are surging in Monday morning trading. The stock is higher following a series of positive updates regarding its lead drug candidate for multiple sclerosis. 
Via Benzinga
BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Signs CDMO Agreement for Oral Lucid-MS in Phase 2 MS Trial
Via Investor Brand Network
Quantum BioPharma Signs Agreement to Manufacture Oral Drug Formulation of its Potential Breakthrough Drug Lucid-21-302 (Lucid-MS) for Use in its Upcoming Phase 2 Multiple Sclerosis Trial
From Quantum BioPharma
Via GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) PET Tracer Shows Potential for Monitoring Myelin Integrity in Multiple Sclerosis
Via Investor Brand Network
Quantum BioPharma Announces Very Promising Results from the Massachusetts General Hospital Scientists on the Novel Positron Emission Tomography (PET) Tracer Used to Detect and Monitor Demyelination in Multiple Sclerosis Patients
Ongoing Joint Clinical Study Could Pave the Way for Testing Efficacy of Quantum’s Investigational MS drug, Lucid-21-302 
From Quantum BioPharma
Via GlobeNewswire
Quantum Biopharma Reports Strong Second Quarter with Increased Current and Total Assets, Conversion of all Debentures into Equity, Continued Exclusion of Going Concern, Tripling of Share Price during Quarter, over $500,000 USD Gain in Crypto Assets as of
Unprecedented Quarter Shows Company’s Strong Financial Position and Continued Momentum with its Multiple Sclerosis Clinical Trials and unbuzzdTM Recreational Beverage and Alcohol Metabolizer 
From Quantum BioPharma
Via GlobeNewswire
Quantum Biopharma Reports Positive Phase 1 Safety For Multiple Sclerosis Drug
Quantum Biopharma's subsidiary, Huge Biopharma Australia, has cleared a regulatory milestone for its neuroprotective compound, Lucid-MS, in a Phase 1 trial. 
Via Benzinga
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Reports Positive Phase 1 Safety Results for Lucid-MS
Via Investor Brand Network
Quantum Biopharma Announces Positive Results of the Clinical Study Report (CSR) for the Phase 1 Multiple Ascending Dose (MAD) Clinical Trial of Experimental Multiple Sclerosis Drug Lucid-21-302 (Lucid-MS)
From Quantum BioPharma
Via GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Opposes Motion to Dismiss in $700 Million Market Manipulation Lawsuit
Via Investor Brand Network
Quantum BioPharma Files Reply and Provides Update on Court Case Seeking Damages Against CIBC, RBC and Others in Excess of $700,000,000 USD for Possible Stock Price Manipulation/Spoofing
From Quantum BioPharma
Via GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Portfolio Company Unbuzzd Wellness Launches $5 Million Regulation D Offering
Via Investor Brand Network
Topics Initial Public Offering
Quantum BioPharma Licensee Unbuzzd Wellness Inc. Commences Reg D Capital Raise Campaign to Fund Growth and Possible IPO
This Offering Will Not Dilute Quantum BioPharma Shareholders 
From Quantum BioPharma
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.